Botanix Pharmaceuticals Limited Stock Price

ASX:BOT Community·AU$285.7m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
79 Fair Values set on narratives written by author

Create a narrative

BOT Share Price Performance

AU$0.14

-0.18 (-54.69%)

AU$0.14

-0.18 (-54.69%)

AU$0.14

Fri, 24 Oct 25

Share PriceAU$0.14

BOT Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Exceptional growth potential with adequate balance sheet.

2 Risks

2 Rewards

View Full Analysis

Botanix Pharmaceuticals Limited Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: -0.044
: 34.85%
: -1,492.37%
: 0%

View Full Analysis

About BOT

Founded: 1984
Employees: n/a
CEO: Howie McKibbon
WebsiteView website: www.botanixpharma.com

Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A for treating atopic dermatitis. The company was incorporated in 1984 and is based in West Perth, Australia.